Heart failure & cardiomyopathies
Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM Trial
Authors' conclusion
In patients with symptomatic oHCM, aficamten monotherapy led to superior and rapid treatment benefits across several clinically relevant outcome measures of disease burden compared with metoprolol.
Study context
- Population
- Symptomatic obstructive hypertrophic cardiomyopathy (oHCM) with left ventricular outflow tract gradient (LVOT-G) ≥30 mm Hg at rest and/or ≥50 mm Hg with Valsalva
- Participants
- 88 vs 87
- Comparison
- Aficamten monotherapy vs metoprolol monotherapy
- Aficamtenn = 88
- Metoprololn = 87reference
- Primary endpoint
- Clinical response by number of 5 efficacy outcomes achieved (LVOT-G, NYHA class/Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS), NT-proBNP, pVO2, LA volume index): positive (3 or 4) or complete (all 5) responders
- Follow-up
- 24 weeks
Methodological detailsDose titration based on vital signs and echocardiograms
- Dose titration based on vital signs and echocardiograms
Primary result
As reported in the abstract
Positive or complete responders
P < 0.001
Secondary outcomes
Individual efficacy outcome measures · 24 weeks
- Greater benefits with aficamten in all efficacy outcomes; NNT vs metoprolol
- 1.5 to 5.0
Original publication
Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM Trial. J Am Coll Cardiol. Published 18 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →